A Two-Part, Phase 1, Randomized, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intranasal Octreotide (DP1038) Versus Subcutaneous Sandostatin Injection in Healthy Adult Volunteers

Trial Profile

A Two-Part, Phase 1, Randomized, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intranasal Octreotide (DP1038) Versus Subcutaneous Sandostatin Injection in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2017

At a glance

  • Drugs Octreotide (Primary) ; Octreotide (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Dauntless Pharmaceuticals
  • Most Recent Events

    • 11 May 2017 Status changed from active, no longer recruiting to completed.
    • 04 May 2017 Status changed from recruiting to active, no longer recruiting, according to a Dauntless Pharmaceuticals media release.
    • 04 May 2017 Results published in a Dauntless Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top